FemasysFEMY
FEMY
About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Employees: 34
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more capital invested
Capital invested by funds: $1.8M [Q2] → $1.8M (+$3.86K) [Q3]
0.2% more ownership
Funds ownership: 7.11% [Q2] → 7.31% (+0.2%) [Q3]
0% more funds holding
Funds holding: 26 [Q2] → 26 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
634%
upside
Avg. target
$11.20
928%
upside
High target
$12
1,001%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 19% 1-year accuracy 25 / 130 met price target | 1,001%upside $12 | Buy Reiterated | 27 Nov 2024 |
Chardan Capital Keay Nakae 48% 1-year accuracy 22 / 46 met price target | 634%upside $8 | Buy Maintained | 13 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 19% 1-year accuracy 25 / 130 met price target | 1,001%upside $12 | Buy Reiterated | 12 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 19% 1-year accuracy 25 / 130 met price target | 1,001%upside $12 | Buy Reiterated | 31 Oct 2024 |
HC Wainwright & Co. Emily Bodnar 19% 1-year accuracy 25 / 130 met price target | 1,001%upside $12 | Buy Reiterated | 12 Sept 2024 |
Financial journalist opinion
Based on 3 articles about FEMY published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
Negative
Zacks Investment Research
2 weeks ago
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Neutral
GlobeNewsWire
1 month ago
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control
Neutral
GlobeNewsWire
1 month ago
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
Neutral
GlobeNewsWire
2 months ago
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
Neutral
GlobeNewsWire
2 months ago
Femasys Announces Infertility Clinic Customers from Coast to Coast
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
Neutral
GlobeNewsWire
2 months ago
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products
Positive
Zacks Investment Research
2 months ago
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Neutral
GlobeNewsWire
2 months ago
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial
Charts implemented using Lightweight Charts™